Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Nerandomilast by Boehringer Ingelheim International for Systemic Sclerosis (Scleroderma): Likelihood of Approval
Nerandomilast is under clinical development by Boehringer Ingelheim International and currently in Phase II for Systemic Sclerosis (Scleroderma). According to...
Nerandomilast by Boehringer Ingelheim International for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease): Likelihood of Approval
Nerandomilast is under clinical development by Boehringer Ingelheim International and currently in Phase III for Interstitial Lung Diseases (Diffuse Parenchymal...
Nerandomilast by Boehringer Ingelheim International for Idiopathic Pulmonary Fibrosis: Likelihood of Approval
Nerandomilast is under clinical development by Boehringer Ingelheim International and currently in Phase III for Idiopathic Pulmonary Fibrosis. According to...